Scancell Holdings Plc · LSE:SCLP
Scancell — Investor Presentation (August 2026)
35 slides from Scancell's investor presentation, August 2026
Slide 1: Corporate Presentation
Corporate Presentation August 2026 Active Immunotherapy Ready For Prime Time
Slide 2: Disclaimer
Disclaimer This communication contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “believe”, “expect”, “plan”, “anticipate”, “estimate”, “continue” and similar expressions (as w
Slide 3: Investment Highlights
Investment Highlights Phase 3 ready, pipeline diversity, near term catalysts iSCIB1+: Novel, Phase 3-Ready DNA Validated Platform, Robust, Diversified Solid Financials Through Multiple Therapeutic Vaccine for Melanoma Pipeline with Partnership Opportunities Milestones Compelling clinical benefit acr
Slide 4: Robust, Diversified Pipeline with Partnership Opportunities
Robust, Diversified Pipeline with Partnership Opportunities Lead asset iSCIB1+ ready to enter phase 3 trial Product Modality Indication Target Preclinical Phase I Phase II Phase III Recent & Upcoming Milestones Compelling PFS and OS. Advanced Melanoma SCIB1/ iSCIB1+ (+ipi/nivo) Fast track designatio
Slide 5: SCIB/iSCIB1+ Program in First Line Advanced Melanoma
SCIB/iSCIB1+ Program in First Line Advanced Melanoma 5
Slide 6: Despite Advent of Checkpoint Inhibitors, Significant Unmet Need in Melanoma
Despite Advent of Checkpoint Inhibitors, Significant Unmet Need in Melanoma Melanoma is the deadliest form of skin cancer Many patients do not respond to CPI and have limited Melanoma cases are rapidly rising treatment options in the post-CPI settings Cases of melanoma have tripled in the last 30 ye
Slide 7: iSCIB1+'s Novel Dual Presentation MOA: Robust and Durable Anti-Tumor Response
iSCIB1+’s Novel Dual Presentation MOA: Robust and Durable Anti-Tumor Response Cross-presentation increases potency 100-fold 1. Processing of plasmid by muscle cells 8. Primed T cells migrate systemically to the tumor 2. Secretion of ImmunoBody microenvironment to kill the tumor cells. 3. ImmunoBody
Slide 8: Stratis Allows for Patient-friendly Administration
Stratis® Allows for Patient-friendly Administration Minimal training required, similar workflow to needle and syringe Intramuscular delivery Needle-free (high velocity fluid jet) Hand-held with separate charging station Delivers injectables in ~1/10 of a second Broad global regulatory approval Devel
Slide 9: SCOPE Phase 2b Trial of SCIB/iSCIB1+ in Combination with Checkpoints in 1L Advanced Melanoma
Phase 2b SCOPE trial SCOPE Phase 2b Trial of SCIB/iSCIB1+ in Combination Designed to improve on reported outcomes with SOC: ipi/nivo PFS: 46% at 12m; Pembro: 35% at 12m with Checkpoints in 1L Advanced Melanoma Cohort 1 (n=43, 2 patients non evaluable) 1 SCIB1 SCIB1 and nivolumab & ipilimumab Target
Slide 10: Trial Population Highly Aligned with 1L Melanoma Studies
Phase 2b SCOPE trial Trial Population Highly Aligned with 1L Melanoma Studies Baseline patient characteristics ipi + nivo Nivo+rela IO102/103- SCIB1 (n=43) iSCIB1+ (n=50) Checkmate 067 Relativity 047 pembro Gender Gender Male 65% 42% Male 65% 59% 67% Female 35% 58% Female 35% 41% 33% Age Age <65 47%
Slide 11: Compelling Clinical Benefit Observed Across Multiple Endpoints
Phase 2b SCOPE trial Compelling Clinical Benefit Observed Across Multiple Endpoints iSCIB1+ with ipi/nivo (SCOPE) vs ipi/nivo (Checkmate 067) Real Scancell Scancell BioNTech IO Biotech BMS BMS World iSCIB1+ IMCODE- SCOPE PFS at 22 months = 77% SCOPE 001 Phase 3 Relativity Checkmate Study1 (iSCIB1+ a
Slide 12: Strong Anti-tumor T Cell Responses Generated by iSCIB1+ Correlated with ORR
Phase 2b SCOPE trial Strong Anti-tumor T Cell Responses Generated by iSCIB1+ Correlated with ORR High statistical significance in increased T-cell response post-iSCIB1+ administration observed Patients with broad T-cell responses had better clinical responses in patients 1400 Clinical Number of High
Slide 13: SCIB1 & iSCIB1+ Well Tolerated with No Increase in CPI-Related Toxicities
Phase 2b SCOPE trial SCIB1 & iSCIB1+ Well Tolerated with No Increase in CPI-Related Toxicities Treatment-Emergent Adverse Events amongst HLA matched, evaluable patients in C1, 3 & 4 (n=104) TEAEs, n(%) Related to: SCIB1/iSCIB1+ Related to CPI Dually Related (CPI + IMP) All grades Grade ≥3 All grades
Slide 14: iSCIB1+ Defined Regulatory Path Forward
iSCIB1+ Defined Regulatory Path Forward 14
Slide 15: Accelerated Approval Trial Design of iSCIB1+ in Advanced Melanoma
Accelerated Approval Trial Design of iSCIB1+ in Advanced Melanoma Phase 3 double-blind, randomized registrational study cleared with FDA 11 doses of 8 mg IM iSCIB1+ at Primary: PFS Primary: PFS Additional Weeks 0,1,3,7,13 & 12 weekly Secondary: OS (descriptive) Secondary: OS OS Follow up N = 550 at
Slide 16: Defined Regulatory Path Forward for iSCIB1+
Defined Regulatory Path Forward for iSCIB1+ Building positive momentum through solid regulatory strategy Jan 2026 Received IND clearance from FDA for the Phase 3 trial of iSCIB1+ in advanced melanoma Apr 2026 FDA Fast Track Designation Received CTA approved by MHRA H2 2026 Regulatory submissions in
Slide 17: iSCIB1+ Program in Neoadjuvant/adjuvant melanoma
iSCIB1+ Program in Neoadjuvant/ adjuvant melanoma 17
Slide 18: Phase 1 SCIB1 Monotherapy study in Resectable Melanoma
Phase 1 trial Phase 1 SCIB1 Monotherapy study in Resectable Melanoma In partially and fully resected stage III & IV patients Partially or Fully Resected 1 PR & 3 SDs Observed at 8mg Dose Stage III & IV Adjuvant Patients Patient Demographics % Lung lesions before and after treatment with SCIB1 0.1 -8
Slide 19: Compelling SCIB1 Monotherapy Activity in Neoadjuvant/Adjuvant Melanoma
Phase 1 trial Compelling SCIB1 Monotherapy Activity in Neoadjuvant/ Adjuvant Melanoma Data supports advancement to Phase 2 10 of 16 Patients remained disease-free at 60 months RFS: All patients alive at 39 months cut-off 75% RFS at 39 months cut-off. Surgery + Pembro 3yr RFS: 63% (Stage III only) T
Slide 20: Proposed PoC Open-label, Randomized Study in Neoadjuvant/Adjuvant Setting
Proposed PoC Open-label, Randomized Study in Neoadjuvant/Adjuvant Setting Study builds on demonstration of monotherapy Adjuvant for non-CPR (n = 150 (62% non-CPR)) Neoadjuvant-adjuvant pembrolizumab Arm 1 Arm 1 vs adjuvant pembrolizumab (n=345) – iSCIB1+ Only iSCIB1+ Only SWOG 1801 Surgical Resectio
Slide 21: iSCIB1+ Commercial Opportunity
iSCIB1+ Commercial Opportunity 21
Slide 22: iSCIB1+ Demonstrates Deep and Durable Responses Across Multiple Endpoints
iSCIB1+ Demonstrates Deep and Durable Responses Across Multiple Endpoints in Broad Patient Population Sca nc ell Immunocore Iova nce BM S (In vest igational) ( Inv est igat ional ) ( Inv est igat ional ) (Approv ed, now SOC) iSCIB1+ accel SCIB1/iSCIB1+ Relatlimab + Therapy dosing Brenetafusp Lifileu
Slide 23: Significant Commercial Opportunity for iSCIB1+
Significant Commercial Opportunity for iSCIB1+ Global peak sales potential up to $9bn in both advanced and earlier settings Cutaneous melanoma Global peak sales addressable market in the U.S. potential for iSCIB1+ (Forecasted 2028) ~117,000 patients Projected incidence Growth potential with diagnose
Slide 24: Strong Execution
Strong Execution 24
Slide 25: Experienced leadership executing with pace and precision
Experienced leadership executing with pace and precision Focus and execution drive value Professor Phil L’Huillier Nermeen Varawalla Chief Executive Officer Lindy Durrant Chief Medical Officer Chief Scientific Officer & Founder David Schilansky Mandeep Sehmi Callum Scott Interim Chief Financial Offi
Slide 26: Key Milestones and Development Plans
Key Milestones and Development Plans 2025 H1 2026 H2 2026 H1 2027 H2 2027 H1 2028 H2 2028 H1 2029 iSCIB1+ iSCIB1+ iSCIB1+ NHS CVLP iSCIB1+ IND iSCIB1+ Ph3 Trial Neoadjuvant / Neoadjuvant / iSCIB1+ Ph3 iSCIB1+ Neoadjuvant / Partnership ✓ clearance ✓ initiation adjuvant trial adjuvant trial primary re
Slide 27: iSCIB1+ Has the Potential to Transform The Treatment of Advanced Melanoma
iSCIB1+ Has the Potential to Transform The Treatment of Advanced Melanoma Deep and durable responses Defined regulatory path to Significant commercial with solid safety profile accelerated approval opportunity • Broad clinical benefit across • Phase 3 initiation in the U.S. Multi-billion-dollar mark
Slide 28: Additional Pipeline
Additional Pipeline 28 ¥ SCANCELL
Slide 29: Moditope Off-the-shelf Peptide Vaccine
Moditope® Off-the-shelf Peptide Vaccine Targeting stress-induced post translational modifications ▪ Citrullination occurs due to autophagy induced in Citrullination stressed cells, including cancer cells ▪ Citrullination protects from proteolytic cleavage and creates neo-epitopes ▪ Inflammation indu
Slide 30: Modi-1 Pipeline & Clinical Development
Modi-1 Pipeline & Clinical Development ▪ Multi-cohort basket study conducted at 16 UK clinical sites enrolling over 120 patients ▪ Safety and dose selection confirmed in over 50 patients ▪ Ongoing cohorts evaluating Modi-1 in combination with SOC checkpoint inhibitors ▪ Modi-1 shows strong early eff
Slide 31: GlyMab Therapeutics Ltd
GlyMab® Therapeutics Ltd Platform and pipeline generating tumor glycan specific antibodies Demonstrated production of high affinity glycan-specific IgG1 antibodies in cancers, improved binding kinetics and functional attributes, to be developed into novel T cell engagers. TARGETING THE GLYCOPROTEOME
Slide 32: Thank You
YW SCANCELL Thank You
Slide 33: Appendices
Appendices 33 ¥ SCANCELL
Slide 34: Experienced Board with Expertise In Biotechnology
Experienced Board with Expertise In Biotechnology Dr Jean-Michel Cosséry Chairman Susan Clement Davies Martin Diggle Director Director Dr Ursula Ney Phil L’Huillier Director Director and Chief Executive Officer Dr Florian Reinaud Prof Lindy Durrant Director Director and Chief Scientific Officer 34
Slide 35: Leveraging a Strong Advisory Board
Leveraging a Strong Advisory Board Purposefully mixing KOLs and Industry leaders Pippa Corrie Dirk Schadendorf Alexander Eggermont Georgina Long Eric Rubin Consultant Medical Oncologist, Professor & Director of Department Director & Professor of Immunology, Chair of Melanoma Medical Strategic Adviso
Scancell Holdings — Investor Presentation (August 2026) on 6ix